|
Market Closed -
Bombay S.E.
11:21:44 30/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 2,708.80 INR | -1.26% |
|
-2.96% | +47.12% |
| 09-25 | Caplin Point Laboratories Limited Approves Appointment of D Muralidharan as Whole Time Director | CI |
| 08-14 | Caplin Point Laboratories Limited, Q1 2027 Earnings Call, Aug 12, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Generic Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 2.17B | - | - | |||
| 46.63B | |||||
| 37.98B | |||||
| 12.48B | |||||
| 11.61B | |||||
| 8.92B |
Select your edition
All financial news and data tailored to specific country editions
